Dapsone Monitoring Protocol
All patients starting dapsone require baseline G6PD screening, CBC with differential, reticulocyte count, liver function tests, and renal function tests before initiation, followed by weekly CBC for the first month, monthly for six months, then semi-annually thereafter. 1
Baseline Testing (Before Starting Dapsone)
- G6PD level - Mandatory to identify patients at risk for severe hemolysis 1
- CBC with differential - Establish baseline hemoglobin and white blood cell counts 1
- Reticulocyte count - Baseline hematopoietic function 1
- Liver function tests (AST, ALT, bilirubin) - Screen for hepatic dysfunction 1
- Renal function (serum creatinine) - Identify patients at higher risk for toxicity 1, 2
Follow-Up Monitoring Schedule
Complete Blood Count Monitoring
The FDA-recommended monitoring schedule, endorsed by the FDA Dermatology Advisory Committee, is 1:
- Weekly CBC for the first month - Critical period for detecting early blood dyscrasias
- Monthly CBC for six months - Continued surveillance for hematologic toxicity
- Semi-annually thereafter - Long-term monitoring while on therapy
If significant reduction in leukocytes, platelets, or hemopoiesis occurs, discontinue dapsone immediately and monitor the patient intensively. 1
Liver Function Monitoring
- Baseline and periodic monitoring of liver enzymes is recommended when feasible 1
- Discontinue dapsone if abnormalities develop until the source is established 1
- Monitor for clinical signs: jaundice, right upper quadrant pain, dark urine 1
Clinical Monitoring at Every Visit
Hemolysis surveillance - Most common adverse effect:
- Monitor for pallor, fatigue, dark urine, jaundice 1
- Hemoglobin typically drops maximally at 2 months (mean decrease 1.29 g/dL), then recovers by 3 months even with continued therapy 3
- 22-27% of patients develop significant anemia despite normal G6PD 4, 2
- Check reticulocyte count, LDH, indirect bilirubin, and peripheral blood smear if hemolysis suspected 3, 5
Methemoglobinemia monitoring:
- Watch for cyanosis (especially with oxygen saturation-hemoglobin discordance), shortness of breath, chocolate-brown blood 6, 7, 8
- Risk increases with dapsone doses >1.5 mg/kg ideal body weight 2
- Patients on long-acting oxidants like dapsone may require repeat methylene blue dosing every 6-8 hours for 2-3 days 6
Agranulocytosis/blood dyscrasia warning signs:
- Sore throat, fever, unusual bleeding or bruising, purpura 1
- Deaths have been reported from agranulocytosis and aplastic anemia 1
Peripheral neuropathy:
- Assess for numbness, tingling, weakness in extremities at each visit
- Motor and sensory examination
Dermatologic reactions:
- New rashes, blistering, mucosal involvement 1
- Severe cutaneous reactions (toxic epidermal necrolysis, exfoliative dermatitis) require immediate discontinuation 1
Critical Caveats
Hemolysis occurs even with normal G6PD: Research demonstrates 22-27% of transplant recipients with normal G6PD develop significant dapsone-induced anemia 4, 2. The lung transplant population shows 5-fold higher rates than HIV patients 2.
High-risk populations requiring more intensive monitoring:
- Renal impairment - Each 1.0 mg/dL increase in creatinine increases hemolysis odds ratio by 4.75 2
- Low body weight - Doses exceeding 1.5 mg/kg ideal body weight increase hemolysis risk 2
- Patients on folic acid antagonists (pyrimethamine, trimethoprim) - Monitor more frequently due to additive hematologic effects 1
- Severe cardiopulmonary disease - May poorly tolerate hemolysis and methemoglobinemia 1
Drug interactions affecting monitoring:
- Rifampin lowers dapsone levels 7-10 fold but may paradoxically enhance methemoglobinemia risk when combined with other oxidants 1, 7
- Trimethoprim raises dapsone levels by 40-50% 1
Do not use methylene blue for methemoglobinemia in G6PD-deficient patients - It will worsen hemolysis and may be ineffective; use ascorbic acid or exchange transfusion instead 6.